Quest Diagnostics has been a hot topic recently in investor and financial circles. The diagnostics services company continues to make strategic moves to further its growth, even in the face of industry threats. The company is set to host its Investor Day and unveil its future roadmap on March 19, 2025. Several acquisitions have taken place, such as the purchase of lab assets from OhioHealth and the Outreach Lab Services Business of University Hospitals. Furthermore, the firm claims to enhance diagnostic services for Canadians by acquiring LifeLabs. The company has also begun a promising partnership with Grail, which resulted in a 30% rally in Grail's shares. Other noteworthy moves include launching a revolutionary cancer detection test available at Quest Labs across the nation and increasing the quarterly dividend by 6.7% to $0.80 per share. New top-tier leadership contributes to strategic shifts, with Adrienne Brott becoming Senior VP and Chief Quality Officer. Despite some share sell-offs from various trusts and investment groups, the momentum of the stock is high, suggesting ample confidence among investors. Finally, the Q4 2024 results topped estimates, justifying the strong growth and revenue increase.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 15 Feb 2025 09:54:36 GMT -
Rating 7
- Innovation 6
- Information 7
- Rumor -5
